New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Muscle GrowthIntermediate

Sarcopenia & Age-Related Muscle Loss Prevention Protocol

Sarcopenia & Age-Related Muscle Loss Prevention Protocol framework focused on consistent execution, practical monitoring, and safer progression.

A protocol for adults 60+ or those experiencing accelerated muscle loss, targeting the multiple drivers of sarcopenia: declining IGF-1/GH axis, myostatin excess, mitochondrial dysfunction, and inadequate satellite cell response to exercise.

Who it's for

People in Adults 60+ with confirmed or suspected sarcopenia; also applicable to cancer survivors programs with clinician oversightUsers running sarcopenia & age-related muscle loss prevention protocol with structured routinesPost-hospitalization patients

Use this as an educational framework with clinical oversight. Keep timing consistent, track response daily, and change one variable at a time after trend review. Pair protocol use with sleep, nutrition, and recovery fundamentals.

Free Peptide Guide

Sarcopenia & Age-Related Muscle Loss Prevention Protocol Protocol PDF

Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.

Free, no spam. No catch.

Free access. No spam. This form sends the shared peptide guide that is live today.

Protocol at a Glance

Cycle Duration

Ipamorelin and MOTS-c: continuous. IGF-1 LR3: 4 weeks on/4 weeks off. Follistatin 344: 10 days on/20 days off. Others continuous.

Target Audience

Adults 60+ with confirmed or suspected sarcopenia; also applicable to cancer survivors, post-hospitalization patients, and those with chronic disease-associated muscle wasting

CompoundDoseFrequency
IGF-1 LR3

IGF-1 LR3: directly restores declining IGF-1 axis; activates satellite cells and stimulates muscle protein synthesis; most effective with resistance training

20-40 mcg/kgDaily SC for 4-week blocks
Ipamorelin

Ipamorelin: restores age-related GH pulsatility decline; improves lean mass and reduces visceral fat; safe for long-term use without cortisol or prolactin effects

100-200 mcgDaily SC
Follistatin 344

Follistatin 344: inhibits myostatin which rises with aging and drives type II fiber atrophy; unlocks anabolic response to resistance training in elderly

100 mcgWeekly SC (10-day on, 20-day off cycles)
MOTS-c

MOTS-c: restores AMPK-driven mitochondrial biogenesis in aging muscle; improves exercise capacity; circulating levels naturally decline with aging

5-10 mgDaily SC
Carnosine

Carnosine: muscle carnosine declines 10% per decade; supplementation buffers exercise-induced acidosis; improves time-to-fatigue in elderly during resistance training

2 gTwice daily oral
NAD+

NAD+: restores SIRT1-mediated proteostasis and mitophagy in aging muscle; prevents accumulation of damaged mitochondria driving fiber atrophy

500 mg NMNOnce daily oral

Free Peptide Guide

Sarcopenia & Age-Related Muscle Loss Prevention Protocol Protocol PDF

Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.

Free, no spam. No catch.

Free access. No spam. This form sends the shared peptide guide that is live today.

Daily Schedule

  1. Morning

    Baseline review and first execution window

    Log sleep, energy, and tolerance; complete planned IGF-1 LR3 timing if scheduled.

  2. Midday

    Adherence and symptom check

    Review hydration, workload, and side effects before any changes.

  3. Evening

    Recovery closeout and next-day setup

    Record outcomes, maintain schedule consistency, and prepare next-day protocol.

Safety

  • Escalating side effects or new concerning symptoms require prompt clinical review.
  • Avoid abrupt multi-compound changes during unstable periods.
  • Maintain regular follow-up with a licensed clinician throughout the cycle.

Not appropriate for unsupervised use or as a replacement for diagnosis and medical care. Use only within a clinician-guided plan.

Who should avoid

  • Anyone using this protocol without qualified medical supervision
  • People with unstable medical or psychiatric conditions without specialist guidance
  • Pregnant or breastfeeding individuals unless explicitly cleared by a physician
Open reconstitution calculator

Common Mistakes

Changing multiple variables at once

Why it matters: This makes it hard to identify what improved outcomes versus what increased side effects.

How to fix: Keep one-variable changes per review cycle and log response for several days.

Ignoring adherence and recovery fundamentals

Why it matters: Protocol effectiveness drops when sleep, nutrition, and routine consistency are unstable.

How to fix: Protect daily anchors first, then optimize protocol details gradually.

FAQ

How long should Sarcopenia & Age-Related Muscle Loss Prevention Protocol run before reassessment?

A common window is Ipamorelin and MOTS-c: continuous. IGF-1 LR3: 4 weeks on/4 weeks off. Follistatin 344: 10 days on/20 days off. Others continuous., with periodic review of tolerance and objective trends.

Can I increase complexity quickly for faster results?

Usually no. Safer optimization comes from staged changes and clear tracking.

What should I track each day?

Track schedule adherence, symptoms, sleep quality, and any adverse effects in one log.

Key Takeaways

  • Consistency with IGF-1 LR3 + Ipamorelin execution matters more than frequent protocol changes.
  • Single-variable adjustments improve safety and decision quality.
  • Objective daily tracking supports better long-term outcomes.

Why This Stack Works

Sarcopenia affects 30% of adults over 60 and is driven by convergent mechanisms: declining IGF-1 and GH pulsatility, rising myostatin, mitochondrial dysfunction in type II muscle fibers, and impaired satellite cell activation. IGF-1 LR3 directly restores the anabolic signaling that declines with aging, activating satellite cells and stimulating protein synthesis across all muscle groups. Ipamorelin restores the GH pulsatility that drops 15% per decade after 30, improving lean mass and reducing visceral fat. Follistatin 344 inhibits myostatin, which increases with aging and is a primary driver of type II fiber atrophy. MOTS-c activates AMPK to restore mitochondrial biogenesis in aging muscle fibers. Carnosine levels in muscle decline 10% per decade and its restoration buffers exercise-induced acidosis, improving training capacity. NAD+ restores SIRT1-mediated proteostasis in aging muscle.

Clinical Research

No clinical references were provided for this stack yet.

More Muscle Growth Stacks

Medical disclaimer: This protocol is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.

Free Peptide Guide

Sarcopenia & Age-Related Muscle Loss Prevention Protocol Protocol PDF

Schedule template, practical checkpoints, common mistakes, and safety guidance in one quick reference.

Free, no spam. No catch.

Free access. No spam. This form sends the shared peptide guide that is live today.